Stay informed with the latest litigation news. Explore now

IP Verse

Amgen competitive analysis

Latest publications and patents of Amgen New

Explore the latest publications and patents granted to Amgen, showcasing their recent innovations and technological advancements.

Last updated on: Sep 4, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Amgen

EP4384159
Aug 20, 2025Heterocyclic Compounds And Methods Of UsePending
EP3592403
Aug 20, 2025Drug Delivery Device With Activation Prevention FeatureGranted
EP4595965
Aug 6, 2025Heteroalkyl Dihydroquinoline Sulfonamide CompoundsPending
EP4593837
Aug 6, 2025Sotorasib Dosing RegimenPending
EP4593831
Aug 6, 2025Combinations Of A B-Raf Inhibitor, And An Anti-Egfr Antibody For The Treatment Of CancerPending
EP4321870
Jul 30, 2025Methods For The Preparation Of Trypsin-Resistant Polypeptides For Mass Spectrometric AnalysisGranted
EP4589002
Jul 23, 2025Use Of Monensin To Regulate Glycosylation Of Recombinant ProteinsPending
EP4587800
Jul 23, 2025Just-In-Time Learning With Variational Autoencoder For Cell Culture Process Monitoring And/Or ControlPending
EP4587548
Jul 23, 2025A Method For Harvesting Products From Perfusion CulturesPending
EP4587474
Jul 23, 2025Bispecific Molecule Stabilizing CompositionPending

Latest oppositions filed by Amgen

Explore patent oppositions filed by Amgen against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 11, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4252857
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSJun 23, 2025
EP3167888
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of ComplementALEXION PHARMACEUTICALSOct 28, 2024
EP3384049
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VegfREGENERON PHARMACEUTICALSApr 22, 2024
EP3536712
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSFeb 29, 2024
EP3345607
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABJul 26, 2023
EP2894165
Methods And Compositions For Treating Complement-Associated DisordersALEXION PHARMACEUTICALSMay 17, 2023
EP3716992
Use Of A Vegf Antagonist To Treat Angiogenic Eye DisordersREGENERON PHARMACEUTICALSMay 10, 2023
EP3230316
Treatment Of Age Related Macular Degeneration With A Small Active Choroidal Neovascularization LesionBAYER HEALTHCAREOct 5, 2022
EP2825558
Combination Therapy For The Treatment Of Ovarian CancerF HOFFMANN LA ROCHEFeb 17, 2020
EP2756004
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSDec 27, 2019

Latest patents of Amgen opposed by its competitors

Explore Amgen's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3661562
Oct 2, 2024Method Of Conjugation Of Cys-Mabs1
EP3570885
Sep 18, 2024Method Of Treating Or Ameliorating Metabolic Disorders Using Glp-1 Receptor Agonists Conjugated To Antagonists For Gastric Inhibitory Peptide Receptor (Gipr)3
EP4209499
Aug 7, 2024Charged Depth Filtration Of Antigen-Binding Proteins7
EP3819007
Jul 10, 2024Dosing Regimen For Anti-Bcma Agents2
EP3926051
May 8, 2024Methods For Harvesting Mammalian Cell Cultures1
EP3151882
Apr 10, 2024Controllable Drug Delivery System And Method Of Use2
EP2637670
Mar 13, 2024Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
EP4058148
Mar 13, 2024Dosing Regimen For Anti-Bcma Agents3
EP3152694
Mar 6, 2024Systems And Methods For Remotely Processing Data Collected By A Drug Delivery Device1
EP3615066
Dec 27, 2023Formulations Of Human Anti-Rankl Antibodies, And Methods Of Using The Same1

Latest PTAB cases involving Amgen New

Discover the latest PTAB cases involving Amgen, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 10, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Amgen

IPR2025-00602Feb 28, 2025AMGENBRISTOL MYERS SQUIBBPending Director Review
IPR2025-00603Feb 28, 2025AMGENBRISTOL MYERS SQUIBBPreliminary response waived
IPR2025-00601Feb 28, 2025AMGENBRISTOL MYERS SQUIBBPending Director Review
IPR2023-00106Nov 2, 2022REPLIMUNEAMGENTerminated-Settled
IPR2021-00528Feb 10, 2021PFIZERAMGENTerminated-Settled
IPR2021-00326Dec 15, 2020LUPINAMGENInstitution Denied
IPR2020-00314Dec 20, 2019FRESENIUS KABI USAAMGENTerminated-Settled
IPR2019-01183Jun 8, 2019FRESENIUS KABI USAAMGENTerminated-Settled
IPR2019-00971Apr 14, 2019FRESENIUS KABI USAAMGENInstitution Denied
IPR2019-00791Mar 7, 2019KASHIV BIOSCIENCESAMGENTerminated-Settled

Top competitors of Amgen

Top competitors of Amgen based on patent oppositions.